Abstract
Background. Obesity associates with cardiometabolic disruptions. Lifestyle changes and pharmacologic therapies show moderately effective results. (‐)‐Epicatechin (EPI), the most abundant flavanol in cacao, has been associated with better cardiometabolic health.Objective. To assess the effect of EPI in humans and explain findings through a preclinical study.Methods. In humans, we performed a single‐dose of EPI oral metabolic tolerance test and a 1‐week trial, measuring cardiometabolic endpoints. In rats, we induced weight gain and cardiometabolic disruptions by a high‐fat diet; afterwards, EPI was daily administered for 15 days. Weight gain, glycemia, arterial pressure, triglyceridemia, and HDL‐cholesterol were measured; also, immonublot in skeletal muscle and adipose tissue were performed.Results. EPI enhanced lipid oxidation and attenuated hyperglycemia and hypertriglyceridemia during postprandial metabolism. EPI induced weight‐loss, fat loss, and improved cardiometabolic endpoints in humans. In rats, EPI reduced weight gain, blood triglycerides, and hyperglycemia. EPI increased the expression of sirtuins, PCG‐1α, mitofilin, UCP.Conclusions. EPI improved several cardiometabolic risk factors in both humans and animals by modulating energy metabolism. These findings make EPI an attractive candidate for human use in regards of treating obesity and its associated comorbidities.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
